1. Nanoparticles in Biotechnology, Drug Development and Drug
Delivery
Report Details:
Published:September 2012
No. of Pages: 160
Price: Single User License – US$4850
•The global market for nanoparticles in biotechnology, drug development and drug delivery was
valued at $17.5 billion in 2011 and should reach nearly $21.6 billion in 2012. Total market value is
expected to reach $53.5 billion in 2017 after increasing at a five-year compound annual growth
rate (CAGR) of 19.9%.
•Drug delivery systems are expected to increase from $11.3 billion in 2012 to $30.9 billion in 2017,
a CAGR of 22.2%.
•Drug development and formulation should total nearly $9.4 billion in 2012 and nearly $20.5 billion
in 2017, a CAGR of 16.9%.
REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This study provides a comprehensive analysis of the market for nanoparticles in the life sciences
on a global basis. Particular attention is given to drug development and formulation and the
development of new drug delivery systems. Its aim is to provide a range of information, from
detailed product analyses within health and wellness subsegments to overall industry trends in
order to quantify and qualify the market for drug products for treating various disease conditions in
both men and women. The applicability of specific types of nanoparticles for specific applications
is discussed.
Forecasts and trends are developed from a cross-reference of data points gleaned from
proprietary industry sources, company publications, industry benchmarking and other divergent
data sources to arrive at a cogent and coordinated forecast.
REASONS FOR DOING THE STUDY
For companies with an effective strategy, market opportunities await. Importantly, the ability to

2. develop an effective strategy begins with knowing where opportunity exists and ends with a plan to
effectively execute in order to capture profit from opportunity.
The nanoparticle drug/delivery market presents an increasingly significant part of the overall
pharmaceutical product market worldwide. This study investigates the specific classes of
nanoparticles and the pharmaceutical products associated with them. Existing drug products and
potential drugs in the pipelines of the major pharmaceutical players in this market are reviewed.
Growing health concerns in developing countries are expected to continue to contribute
substantially to market growth through the forecast period (2012 through 2017). This report
analyzes emerging markets by technology category. Continued growth is expected in emerging
geographies driven by the health awareness of the growing middle class in emerging countries
such as India, China, Brazil and Russia.
This report seeks to address the critically important topics of analyzing a changing market
dynamic, emerging players and products, strategies for accessing emerging markets and
awareness of specific disease prevalence and geographies thereof in order to allocate resources
and make effective decisions.
SCOPE OF REPORT
Current and projected product forecasts during the forecast period of 2012 through 2017 are
discussed. New product launches will be discussed. Revenue figure for 2011 are in an actual
figures except where actual results have not been reported due to the timing of this report’s
release.
The report includes analysis of leading and emerging drug products for each nanoparticle type.
Profiles of manufacturers of leading products and their specific products are provided. This report
also assesses companies poised to introduce products during the forecast period and discusses
how these introductions will change the face of the competitive environment. The competitive
environment is examined with a special focus on how new products will alter the quality of life of
patients receiving nanoparticle-associated drugs.
Market figures are based on revenues at the manufacturer level and are projected at 2011 dollar
value. Inflation is not computed into the projection figures. Trends are assessed based on
projected sales for existing products, for new product introductions, expanded markets for existing
products and other factors affecting the market.
Included in this report are forecasts by product, product category and by company from 2010
through 2017. The study is arranged to offer an overview of existing nanoparticle technology and
of drug markets; it is accompanied by nanoproduct, company, geography, and mechanism of
action, with forecasts broken down and covered by geographic region or country.

3. Patent and clinical trial information is reviewed for various candidate nanodrugs. The status of
approvals of drugs in each segment by the FDA and regulatory agencies in other countries is
reviewed.
Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the
performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis unless specifically noted.
INTENDED AUDIENCE
This report is an invaluable tool for business planners, acquisitions specialists, licensing
strategists, product managers, market research analysts, investors, investor consultants and
anyone interested in the nanoparticle drug market, its products, its industry participants and its
future.
The importance of identifying overall market trends, product opportunities, emerging geographies,
merger and acquisition (M&A) opportunities and insights that provide guidance for sales growth or
defensive moves cannot be overstated for a variety of constituents, including:
Established companies in the industry shall benefit from the contents, including corporate strategy,
sales and marketing, business development and R&D.
Emerging players in the segment must understand specific opportunities for out-licensing
originating from the elements of differentiation of their product or technology as compared to
leading, competitive and emerging products. As well, market forecasts can support investment
provided a thorough and detailed substantiation is provided for the market forecast, as is found in
this study.
Investment firms evaluating candidates for venture capital or hedged investments will gain insights
as to the opportunities and risks that are being encountered in the industry in a product- and
company-specific analysis.
Equity analysts are provided detailed forecasts for the next five years, substantiated by
quantitative analysis that can support further analysis to product and company forecasts over the
short and long run.
METHODOLOGY AND INFORMATION SOURCES
In-depth interviews were conducted with leading experts in the field who are executives in
companies, industry analysts, and leading individuals in the field.

4. The nanoparticle biomedical technology market is comprised of drug products for treatment of an
assortment of specific diseases of both men and women. For completeness, the current and
forecasted markets are comprised of the total market opportunity for each respective segment.
Within each subsection there are detailed forecasts for each driving mechanism or relevant area of
growth.
Information to prepare this report was obtained from participating and emerging companies in the
nanoparticle area and from the National Institute of Kidney and Urologic Diseases Information
Clearinghouse (NKUDIC), a service of Nat. Inst. of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Library of Medicine (NLM, NIH). Additional information was obtained from a
variety of medical and technical journals in the various specialties of the nanoparticle applications.
Other sources include: the New York Times, Wall Street Journal, Washington Post, other
newspapers, company documents and other websites. Population estimates are based on those
reported by the International database of the U.S. Census Bureau. Statistical data was obtained
from the World Health Organization (WHO), National Institute of Health (NIH) and WHO
Collaborating Centre for Drug Statistics Methodology (Norway).
Current and historical revenue figures for individual products have been sourced from company
disclosures that exist in the public domain or from government sources.
ANALYST CREDENTIALS
Jackson Highsmith is a life sciences research consultant with more than 16 years of research
experience. Jackson has been consulting with specialty pharmaceuticals and large
pharmaceutical industry players since 2007. Prior to that, he worked at a large research
consultancy where he focused on in-depth research; he also has worked at a large pharmaceutical
company in a wide range of medical therapeutics in early- and mid-stage drug development.
Get your copy of this report @
http://www.reportsnreports.com/reports/195543-nanoparticles-in-biotechnology-drug-development-and-drug-
delivery.html
Major points covered in Table of Contents of this report include
Table Of Contents
Chapter- 1: Introduction - Complimentary 4
Study Goals And Objectives
Reasons For Doing The Study
Scope Of Report
Intended Audience
Methodology And Information Sources
Analyst Credentials

5. Related Bcc Reports
Bcc On-Line Services
Disclaimer
Chapter- 2: Summary 2
Table Summary : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals,
Through 2017
Figure Summary : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals, 2010-
2017
Chapter- 3: Overview 12
Nanoparticle Overview
Brief History Of Nanoparticles
Nanoparticles In Biotechnology
Nanoparticles In Drug Development
Nanoparticles In Drug Delivery Systems
Nanoparticles In Diagnostic Imaging
Major Players In Nanoparticle Drug Delivery Field
Chapter- 4: Global Market For Nanoparticles In Life Science 5
Global Market For Nanoparticles In Biotechnology
Global Market For Nanoparticles In Drug Development
Global Market For Nanoparticles In Drug Delivery Systems
Global Market For Nanoparticles In Diagnostic Imaging
Table 9 : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals, Through 2017
Chapter- 5: Nanoparticles Structure 6
Adoption Of Nanoparticles In Applied Markets
Chapter- 6: Nanoparticle Production 9
Method Of Nanoparticle Formation
Self-Assembly Production
Methods Of Stabilization
Methods Of Drug Introduction
Methods Of Loading Biological Molecules Into Nanoparticles
Nanocrystal Drugs
Problem With Large-Scale Nanoparticle Production
Chapter- 7: Nanoparticles In Biotechnology 7
Research And Development
Stem Cell Research
Cellular Repair

6. In Vitro Imaging
Paramagnetic And Superparamagnetic Nanoparticles
Biosensors And Quantum Dots
Table 17 : Nanoparticles In Biotechnology Applications
Chapter- 8: Nanoparticles In Drug Development And Formulation 12
Bioseparations
Rapid Drug Analysis
Removal Of Impurities And Toxins
Using Nanoparticles To Incorporate Insoluble Drugs
Screening/Profiling Drug Candidates
Combining Antibodies And Drugs Into Nanoparticles
Gold And Silver Nanoparticles In Biomedicine
Dna Nanoparticle Development Of Dna-Specific Drugs
Table 19 : Nanoparticles In Drug Development Applications
Chapter- 9: Nanoparticles In Drug Delivery Systems 39
Nanoparticles In Drug Delivery Applications
Designing A Nanoparticle Drug Delivery System
Nanoparticle Drug Stability
Size Homogeneity Of Nanoparticle Preparations
Drug Loading Of Nanoparticles
Drug Release From Nanoparticle
External Triggers For Releasing Drug From Nanoparticles
Binding/Incorporation Of Biomolecules To Nanoparticles
Nanoparticle Toxicity
Large-Scale Manufacturing
Methods Of Administration Of Nanoparticle Drugs
Nanoparticle Drug Delivery System Currently Available
Removal Of Nanoparticles From The Body
Chapter- 10: In Vitro And In Vivo Diagnostic Imaging 3
In Vitro Imaging
Nanoparticles In Diagnostic Imaging
Chapter- 11: Biomedical Nanoparticle Products 21
Current Fda-Approved Nanoparticle Drug Products
Major Players In Nanoparticle Drug Delivery Systems
Company Pipelines For Nanoparticle Drug Delivery
Drivers Of Nanoparticle Products And Marketing
Limiters Of Nanoparticle Product Development And Marketing

7. Chapter- 12: Global Market For Nanoparticle Drugs And Delivery Systems 3
The Global Market
Chapter- 13: Clinical Trials Of Nanoparticle Drugs And Drug Delivery Systems 6
Table 43 : Clinical Trials For Nanoparticle Drugs And Drug Delivery Systems
Table 44 : Clinical Trials For Nanoparticle Drugs And Drug Delivery Systems
Table 45 : Clinical Trials For Nanoparticle Drugs And Drug Delivery Systems
Chapter- 14: Patents, Licensing, Mergers And Acquisitions 11
Nanoparticle Patents
U.S. Patents For Nanoparticles Drug Development
U.S. Patents For Nanoparticle Drug Delivery
Quantum Dot Patents
Table 46 : Major Licensing, Collaborative Partnerships And Merger And Acquisition Activities
Chapter- 15: Company Profiles 20
Abraxis Biosciences, Inc
Abraxis Pharmaceutical Products
Access Pharma, Inc.
Alnylam Pharmaceuticals, Inc.
Amag Pharmaceuticals, Inc.
Aphios Corporation
Asklepios Biopharmaceutical, Inc.
Astrazeneca Pharmaceuticals, Plc
Bind Biosciences, Inc
Cerulean Pharma Inc.
Convatec
Debiotech, S.A.
Elan Pharmaceuticals, Inc.
Flamel Technologies, Inc
Ge Global Research
Magforce Nanotechnologies Ag
Miv Therapeutics Inc.
Nanocarrier Co., Ltd.
Nano Interface Technology, Inc
Nanosphere, Inc.
Novartis International Ag
Pharmasol Corporation
Skyepharma, Plc
Starpharma Holdings, Ltd
Talon Therapeutics, Inc.
T2 Biosystems Inc.

8. List Of Tables
Summary Table : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals,
Through 2017
Table 1 : Description Of Nanoparticles Used In Drug Delivery And Diagnostic Imaging
Table 2 : Application Of Nanoparticles In Biotechnology
Table 3 : Application Of Nanoparticles In Drug Development
Table 4 : Application Of Nanoparticles In Drug Delivery Systems
Table 5 : Nanoparticle Drug Delivery Systems
Table 6 : Nanoparticles Used For In Vivo Diagnostic Imaging
Table 7 : Major Players In Nanoparticle Drug Field
Table 8 : Major Player Company Revenues For Nanoparticle Drugs, Through 2017
Table 9 : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals, Through 2017
Table 10 : Global Revenues Biotechnology Applications Of Nanoparticles, Through 2017
Table 11 : Global Market For Nanoparticles In Drug Development And Formulation, Through 2017
Table 12 : Global Revenues From Nanoparticles In Drug Delivery Systems, Through 2017
Table 13 : Global Revenues From Nanoparticles In Diagnostic Imaging Systems, Through 2017
Table 14 : Nanoparticle Structure And Properties
Table 15 : Sample Of Drugs Delivered Through Liposome Nanotechnology
Table 16 : Approved Nanocrystal Drugs
Table 17 : Nanoparticles In Biotechnology Applications
Table 18 : Nanobiosensor Technology Under Development
Table 19 : Nanoparticles In Drug Development Applications
Table 20 : Monoclonal Antibody (Mab) Drugs With Potential For Use In Nanoparticle Delivery
Systems
Table 21 : Solid Lipid Nanoparticle-Reformatted Drugs
Table 22 : Nanoparticles In Drug Delivery Applications
Table 23 : Standard Routes Of Drug Administration
Table 24 : Nanoparticle Transdermal Patch Products
Table 25 : Types Of Nanoparticles Supplied In Drug Delivery Systems
Table 26 : Nanocrystal Drugs Approved By The Fda
Table 27 : Mechanisms For Removal Of Nanoparticles From The Body
Table 28 : Nanoparticle Contrast Media Used For In Vivo Diagnostic Imaging
Table 29 : Current Fda-Approved Nanoparticle Drug Delivery Systems
Table 30 : Fda-Approved Drugs Specifically For Cancer Treatment
Table 31 : Fda-Approved Drugs For Central Nervous System Diseases
Table 32 : Major Players In Nanoparticle Drug Development And Formulation Market
Table 33 : Company Pipeline For Cardiovascular Nanoparticle Drugs
Table 34 : Company Pipeline For Cns Disease Nanoparticle Drugs
Table 35 : Company Pipeline For Gi Disease Nanoparticle Drugs
Table 36 : Company Pipeline For Infectious Disease Nanoparticle Drugs

9. Table 37 : Company Pipeline For Cancer Nanoparticle Drugs
Table 38 : Company Pipeline For Ophthalmic Nanoparticle Drugs
Table 39 : Company Pipeline For Autoimmune Disease Nanoparticle Drugs
Table 40 : Global Market For Nanoparticle Drugs And Diagnostic Imaging, Through 2017
Table 41 : Global Market For Nanoparticle Drug Development And Formulation And Drug Delivery
Systems, Through 2017
Table 42 : Global Market For Diagnostic Imaging And In Vitro Imaging, Through 2017
Table 43 : Clinical Trials For Nanoparticle Drugs And Drug Delivery Systems
Table 44 : Clinical Trials For Nanoparticle Drugs And Drug Delivery Systems
Table 45 : Clinical Trials For Nanoparticle Drugs And Drug Delivery Systems
Table 46 : Major Licensing, Collaborative Partnerships And Merger And Acquisition Activities
Table 47 : Global Percentage Share Of Patents Issued By Geography, From 2008 To 2011
Table 48 : U.S. Patents For Nanoparticle Drug Development
Table 49 : U.S. Patents For Nanoparticle Drug Delivery
Table 50 : U.S. Patents For Quantum Dot Technology Applied To Medical Applications
List Of Figures
Summary Figure : Global Market For Nanoparticles In Biotechnology And Pharmaceuticals, 2010-
2017
Contact: sales@reportsandreports.com for more information.